Parse Biosciences Launches Integrated Immune Repertoire and Whole Transcriptome Analysis in Trailmaker™

26 January 2026 | Monday | News

New Trailmaker functionality unifies single-cell immune profiling to deliver rapid, publication-ready insights and an end-to-end workflow for immunology research

New Trailmaker functionality integrates immune repertoire and whole transcriptome data to deliver rapid, publication-ready insights

Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions,  announced the launch of a fully integrated immune repertoire and whole transcriptome analysis workflow in its data analysis platform, Trailmaker™. The new functionality complements Parse’s existing portfolio of Evercode immune products to enable a full end-to-end workflow for researchers.

Immunologists have lacked an integrated, purpose-built platform capable of connecting immune repertoire data with whole transcriptome single cell insights. As a result, interpreting clonal behavior, understanding functional cell states, and drawing meaningful biological conclusions has often required stitching together fragmented tools, custom code, or inconsistent visualization approaches. The new Trailmaker functionality directly addresses these challenges by providing an accessible, end-to-end immune profiling solution that brings repertoire and transcriptional information together in a cohesive environment.

The new functionality combines immune repertoire and whole transcriptome data to give researchers a complete view of clonal structure, diversity, and antigen-driven signatures. Users can visualize clonotypes and cell types on an integrated UMAP, quickly identify dominant clones with frequency and honeycomb plots, and use unique motif analysis to detect conserved patterns. By linking repertoire data with full transcriptome expression, Trailmaker makes it easy to connect clonotypes to their transcriptional states, reveal clonotype-specific gene programs, and run targeted differential expression, delivering deeper, more contextualized biological insights.

“Our goal has always been to remove barriers for researchers,“ says Charlie Roco, PhD, Co-founder and Chief Technology Officer at Parse. “By making immune profiling intuitive and more fully integrated, we’re empowering immunologists to spend less time wrangling the data and more time assigning biological significance.”

 

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close